Is H. Pylori Deadly? When to Be Concerned

H. pylori infections are extremely common and rarely deadly on their own, but the bacterium can set the stage for serious problems when left untreated over years or decades. More than half the world’s population carries H. pylori, and most of those people never develop symptoms at all. The genuine danger lies in what the infection can become: peptic ulcers that bleed, or, in a small fraction of cases, stomach cancer. Understanding where you fall on that risk spectrum matters far more than the infection itself.

How Common H. Pylori Actually Is

Roughly half of all humans are infected with H. pylori, making it one of the most widespread bacterial infections on earth.¹ The rates vary enormously depending on where you live and how you grew up. In parts of Africa, Central and South America, and some regions of Asia, prevalence still exceeds 80%. In Northern Europe and North America, roughly a third of adults are infected.² The pattern tracks closely with sanitation infrastructure and household crowding, because H. pylori spreads from person to person, likely through oral or fecal-oral contact, and usually during childhood.¹

That sheer prevalence is an important piece of context. If half the planet carries the bacterium and stomach cancer remains relatively uncommon globally, the math tells you that the vast majority of infected people live out their lives without the infection causing them serious harm. The question isn’t really whether H. pylori can be dangerous — it can — but under what circumstances the risk goes from background noise to something worth acting on.

What Happens Inside an Infected Stomach

Once H. pylori establishes itself in the stomach lining, it triggers chronic inflammation. In most people, that inflammation simmers at a low level and never progresses further. But over years or decades, a subset of infected individuals develops a recognizable sequence of changes in the stomach lining known as the Correa cascade. The progression runs from ordinary chronic gastritis to a thinning of the stomach lining called atrophic gastritis, then to a transformation of the cells known as intestinal metaplasia, then dysplasia, and finally, in rare cases, stomach cancer.³ Each step in this cascade takes time, which is why stomach cancer from H. pylori typically appears in people who have been carrying the infection for many years.

Not everyone progresses through those steps, and most people stall at the earliest stage. Whether you advance depends on a combination of the specific bacterial strain you’re carrying, your own genetic susceptibility, and environmental factors like diet and smoking. The infection creates the conditions for damage, but the damage itself requires additional contributors.

Not All Strains Are Equal

One of the most important things researchers have learned about H. pylori is that some strains are far more aggressive than others. Two bacterial genes in particular, called cagA and vacA, play outsized roles in determining how much damage the infection causes. Strains carrying these virulence genes are more strongly associated with ulcers, precancerous changes, and cancer itself.⁴ Specific combinations of these genetic variants, along with another gene called babA2, appear to have a synergistic effect, raising the odds of both peptic ulcer disease and precancerous stomach changes more than any single gene would alone.⁵

This is partly why H. pylori outcomes differ so dramatically across populations. In East Asia, where certain high-virulence strains are more common, stomach cancer rates are substantially higher than in regions where milder strains dominate. Two people sitting across from each other at dinner could both test positive for H. pylori and face very different long-term risks, depending on which version of the bacterium they’re carrying. Standard clinical testing doesn’t routinely identify strain virulence, though — treatment decisions are usually based on symptoms and endoscopic findings rather than the genetic profile of the bacterium.

The Cancer Connection

H. pylori is classified as a definite carcinogen, which sounds alarming but needs context. The bacterium increases the risk of two types of stomach cancer: gastric adenocarcinoma, the more common type, and a rarer lymphoma called MALT lymphoma that arises from immune tissue in the stomach lining. For adenocarcinoma, the risk is concentrated in people who have already progressed to more advanced stages of stomach lining changes. Patients who had reached the intestinal metaplasia stage or beyond faced measurable cancer risk even after treatment.⁶

MALT lymphoma is a different story and, in a way, a more hopeful one. This cancer is so directly driven by H. pylori that simply eradicating the bacterium with antibiotics leads to complete remission in about 60 to 90 percent of early-stage cases.⁷ That’s an extraordinary outcome for a cancer diagnosis — curing the underlying infection cures the cancer in the majority of patients.⁸ It also underscores that H. pylori’s relationship to cancer is one of chronic inflammation creating fertile ground, rather than the bacterium directly transforming cells the way a virus like HPV does.

A large cohort study found that among patients with confirmed H. pylori, those who successfully eradicated the infection had roughly 76% lower risk of developing gastric cancer compared to those who didn’t.⁹ A population-level eradication campaign on the Matsu Islands in Taiwan reduced gastric cancer incidence by about 53% compared to historical rates.¹⁰ The evidence strongly favors treating the infection, especially when early stomach-lining changes are already present.

Warning Signs That Deserve Medical Attention

Most people carrying H. pylori feel perfectly fine. When symptoms do appear, they tend to be vague — upper abdominal discomfort, bloating, nausea, or a burning sensation that could easily be mistaken for ordinary indigestion. For uncomplicated symptoms like these, guidelines recommend starting with a noninvasive test for H. pylori, such as a breath test or stool antigen test, rather than jumping straight to endoscopy.¹¹

There are, however, symptoms that should move you from “make an appointment” to “get seen soon.” These are sometimes called alarm features:

• Unintended weight loss: losing weight without trying, especially combined with poor appetite
• Difficulty swallowing: food feeling stuck or painful going down
• Vomiting blood or dark material: a sign of active bleeding in the upper digestive tract
• Black or tarry stools: another marker of bleeding higher up in the gut
• Persistent vomiting: especially if you can’t keep food down for days
• Severe or worsening pain: sudden sharp abdominal pain can indicate a perforated ulcer, which is a medical emergency

Any of these symptoms warrants prompt evaluation, usually including endoscopy, because they raise the possibility of bleeding ulcers or cancer. A perforated ulcer in particular can be life-threatening if not treated quickly. Most people with H. pylori will never face any of these situations, but knowing what signals a genuine emergency can make a real difference in outcomes.

How Doctors Test for H. Pylori

Testing falls into two categories: noninvasive and invasive. For most people without alarm symptoms, the noninvasive route makes sense. Stool antigen tests and urea breath tests are the workhorses, with stool antigen testing showing sensitivity around 96% and urea breath tests around 89% in one head-to-head comparison.¹² Both detect active infection, which is what you need to know for treatment decisions.

Blood tests for H. pylori antibodies are common but less useful on their own, because they can’t distinguish between an active infection and one you cleared years ago. That said, a negative blood test can reliably rule out infection in populations where H. pylori is uncommon.¹³ If your blood test comes back positive, your doctor will typically follow up with a breath test or stool test to confirm whether the infection is still active.

When alarm symptoms are present, or when there’s a need to evaluate the stomach lining directly, endoscopy is the way to go. It allows the doctor to both visualize the stomach and take biopsies, which can be tested for H. pylori and examined for precancerous changes. Patients with severe gastric atrophy, inflammation concentrated in the body of the stomach, or intestinal metaplasia on biopsy are at significantly higher risk for gastric cancer and typically need ongoing surveillance.¹⁴

Treatment and the Growing Problem of Antibiotic Resistance

Treating H. pylori means a course of multiple antibiotics combined with an acid-suppressing medication, usually taken for 10 to 14 days. The classic approach, called triple therapy, pairs two antibiotics with a proton pump inhibitor. A network meta-analysis found that triple therapy still had the highest probability of being the most effective first-line option, followed by quadruple therapy, though dual therapy showed comparable results with better patient compliance.¹⁵

The real complication is antibiotic resistance, which has eroded treatment success rates considerably. Resistance to clarithromycin, long the backbone of standard triple therapy, now exceeds 15% in the majority of countries studied.¹⁶ Levofloxacin resistance is similarly high in most regions.¹⁷ This means the old standard triple therapy, once considered highly reliable, now fails in a substantial number of patients.¹⁸

If your first round of treatment doesn’t work, doctors have several fallback options, including bismuth-based quadruple therapy or regimens using different antibiotics. In one study comparing approaches, a bismuth-containing quadruple regimen achieved about a 74% eradication rate, compared with about 65% for standard clarithromycin-based triple therapy.¹⁹ For patients who fail multiple rounds, rifabutin-based rescue regimens are sometimes used as a last resort.²⁰ The takeaway for patients is that if symptoms persist after treatment, going back for confirmation testing matters — you can’t assume the infection is gone just because you completed the antibiotics.

Why Confirmation Testing Matters

Symptoms alone are a poor gauge of whether treatment actually cleared the bacterium. The American College of Gastroenterology recommends a urea breath test as the most reliable way to confirm eradication, ideally performed at least four weeks after finishing treatment.²¹ Patients who have already failed one round of treatment, or who are suspected of carrying resistant strains, may need antimicrobial sensitivity testing, which requires an endoscopic biopsy to culture the bacteria — though this testing remains limited in availability.

Skipping confirmation testing is common in practice but risky, particularly given rising resistance rates. If the infection survives the first round, it’s more likely to be resistant to the antibiotics you just took, which narrows your options for the next attempt. Catching a treatment failure early gives you and your doctor a better shot at clearing the infection before further stomach lining damage accumulates.

Lifestyle Factors That Amplify or Reduce Your Risk

H. pylori doesn’t act in isolation. Several modifiable factors influence whether a chronic infection leads to serious disease. High salt intake is one of the better-studied examples: a study in China found that people with both H. pylori infection and high salt consumption had roughly double the risk of gastric cancer compared to infected people with lower salt intake. Smoking added further risk, especially for cancers in the main body of the stomach.²²

On the flip side, diets rich in fruits and vegetables appear to be somewhat protective, though the evidence is less clean-cut than for salt and smoking. A family history of stomach cancer is another important risk modifier. If a first-degree relative had gastric cancer and you test positive for H. pylori, most gastroenterologists would consider that a strong indication for treatment even if you have no symptoms.

H. Pylori in Children

Most H. pylori infections are acquired during childhood, and the majority of infected children have no symptoms at all.²³ When symptoms do occur, they tend to be self-limited episodes of belly pain, nausea, or vomiting. Serious complications like bleeding ulcers or cancer are genuinely rare in children.²⁴ The clinical approach in pediatrics is more conservative than in adults — routine screening of asymptomatic children isn’t recommended, and treatment is generally reserved for kids who have confirmed ulcers or significant symptoms.

One area where childhood H. pylori infection does draw clinical attention is its association with iron-deficiency anemia, vitamin B12 deficiency, and a blood-clotting disorder called immune thrombocytopenic purpura. These aren’t common, but they’re worth investigating if a child has an unexplained drop in blood counts or iron levels alongside a known infection.

Effects Beyond the Stomach

H. pylori’s influence extends further than the digestive tract. The bacterium has been linked to immune thrombocytopenic purpura, a condition where the immune system destroys its own platelets, leading to easy bruising and bleeding. Eradication of H. pylori has been shown to improve platelet counts in affected patients, further supporting a causal connection.²⁵ Other proposed extragastric associations include iron-deficiency anemia, cardiovascular disease, and certain hepatobiliary conditions, though the strength of evidence varies across these associations.²⁶

These connections remain an active area of research. For most people, H. pylori is a stomach story. But if you’re dealing with unexplained anemia or a low platelet count and you also carry H. pylori, treating the infection is a reasonable step that sometimes resolves the other problem too.

The Paradox of a Protective Pathogen

Here’s where the picture gets genuinely weird. Despite its classification as a carcinogen and its clear role in ulcers and gastric cancer, H. pylori appears to protect against certain other diseases. Some research suggests that eradicating H. pylori increases the risk of allergic asthma and other allergic conditions.²⁷ And the bacterium that raises the risk of stomach cancer may actually lower the risk of esophageal cancer through several proposed mechanisms, including triggering anti-inflammatory pathways and modifying the esophageal microbiome.²⁸

This paradox makes some evolutionary sense. H. pylori has coexisted with humans for at least 60,000 years, migrating out of Africa alongside our ancestors and evolving into genetically distinct populations that mirror human migration patterns.²⁹³⁰ A bacterium that has spent tens of thousands of years intimately intertwined with human biology isn’t going to have a simple relationship with the host. The modern push toward universal eradication bumps up against the possibility that we’re removing something our immune systems have been calibrated around for millennia.

None of this means you should refuse treatment if you have symptoms, ulcers, or precancerous stomach changes. But it does explain why some researchers argue against treating every asymptomatic carrier, especially in low-risk populations.

What Eradication Therapy Does to Your Gut

The aggressive antibiotic regimens used to kill H. pylori don’t leave the rest of your gut bacteria untouched. Research has shown that eradication therapy significantly reduces many beneficial bacteria, particularly those that produce butyrate, a fatty acid important for colon health. At the same time, some harmful bacteria increase in abundance after treatment.³¹ Taking probiotics alongside or after treatment didn’t boost eradication rates in a multicenter trial, but it did help restore a healthier balance of gut bacteria.³²

This collateral damage is temporary for most people, but it’s another reason that blanket treatment of asymptomatic carriers remains controversial. If the infection isn’t causing you problems and your cancer risk is low, the cost of a broad-spectrum antibiotic course to your gut ecosystem may not be worth the benefit. It’s a conversation to have with your doctor based on your individual risk profile rather than a one-size-fits-all decision.